DRRX Stock Price, Durect Corp Quote, Chart

Market Summary

USD0.94+0.02

Market Closed

2.17%

DRRX Stock Price

View Fullscreen

DRRX RSI Chart

DRRX Valuation

Market Cap

28.6M

Price/Earnings (Trailing)

-1.03

Price/Sales (Trailing)

3.34

Price/Free Cashflow

-0.83

DRRX Price/Sales (Trailing)

DRRX Profitability

Return on Equity

-186.86%

Return on Assets

-61.13%

Free Cashflow Yield

-120.71%

DRRX Fundamentals

DRRX Revenue

Revenue (TTM)

8.5M

Rev. Growth (Yr)

-19.49%

Rev. Growth (Qtr)

53.04%

DRRX Earnings

Earnings (TTM)

-27.6M

Earnings Growth (Yr)

86.24%

Earnings Growth (Qtr)

52.21%

Breaking Down DRRX Revenue

Last 30 days

-28.3%

Last 90 days

16.7%

Trailing 12 Months

-78.0%

How does DRRX drawdown profile look like?

DRRX Financial Health

Current Ratio

1.28

Debt/Equity

1.21

Debt/Cashflow

-1.92

DRRX Investor Care

Shares Dilution (1Y)

30.58%

Diluted EPS (TTM)

-1.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	17.1M	12.8M	10.7M	8.5M
2022	13.7M	13.5M	23.3M	19.3M
2021	30.7M	8.5M	8.9M	14.0M
2020	26.3M	27.6M	28.9M	30.1M
2019	19.2M	19.8M	21.5M	25.1M
2018	48.1M	47.2M	34.5M	18.6M
2017	15.0M	16.1M	33.1M	49.2M
2016	18.0M	16.7M	15.7M	14.0M
2015	17.9M	17.7M	18.2M	19.1M
2014	17.5M	18.1M	19.4M	19.4M
2013	16.0M	15.2M	14.3M	15.3M
2012	66.1M	63.0M	58.7M	53.1M
2011	32.5M	33.0M	33.0M	33.5M
2010	0	26.8M	29.2M	31.6M
2009	0	0	0	24.5M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Durect Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 13, 2023	bleichroeder lp	sold	-	-	-3,498	-
Aug 19, 2022	robertson judith j.	bought	8,000	0.85	9,411	-
Aug 18, 2022	robertson judith j.	bought	60,794	0.8499	71,531	-
Aug 17, 2022	robertson judith j.	bought	8,614	0.84548	10,189	-
Aug 12, 2022	maderis gail j	bought	17,993	0.7139	25,204	-
Aug 11, 2022	maderis gail j	bought	17,322	0.6986	24,796	-
Aug 10, 2022	maderis gail j	bought	54,661	0.6859	79,693	-
Aug 09, 2022	maderis gail j	bought	45,158	0.6423	70,307	-
May 26, 2022	robertson judith j.	bought	25,597	0.3938	65,000	-
May 24, 2022	azab mohammad	bought	11,638	0.387933	30,000	-

Which funds bought or sold DRRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	62.00	121	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	25.85	13,712	22,385	-%
Apr 11, 2024	Silverberg Bernstein Capital Management LLC	reduced	-2.5	27,633	55,276	0.05%
Apr 11, 2024	INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC	new	-	16,928	16,928	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.53	-1,971,940	632,768	-%
Feb 26, 2024	Virtu Financial LLC	new	-	26,000	26,000	-%
Feb 16, 2024	HARBOUR INVESTMENTS, INC.	unchanged	-	-950	295	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	unchanged	-	-27,000	9,000	-%
Feb 15, 2024	BARCLAYS PLC	reduced	-87.98	-99,000	3,000	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	24,416	24,416	-%

Are Funds Buying or Selling DRRX?

Are funds buying DRRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own DRRX

No. of Funds

Unveiling Durect Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 27, 2024	ingalls & snyder llc	8.6%	2,558,012	SC 13G
Feb 16, 2024	asen r scott	5.13%	1,530,000	SC 13G
Feb 14, 2024	lion point capital, lp	0.0%	-	SC 13G/A
Dec 01, 2023	bleichroeder lp	0%	0	SC 13G/A
Feb 14, 2023	bleichroeder lp	11.59%	2,641,463	SC 13G/A
Feb 14, 2023	lion point capital, lp	6.3%	-	SC 13G/A
Jul 08, 2022	blackrock inc.	1.3%	2,925,726	SC 13G
Feb 14, 2022	lion point capital, lp	6.81%	-	SC 13G/A
Feb 09, 2022	vanguard group inc	4.97%	11,295,979	SC 13G/A
Feb 03, 2022	blackrock inc.	6.1%	13,937,117	SC 13G/A

Recent SEC filings of Durect Corp

View All Filings

Date Filed	Form Type	Document
Mar 28, 2024	424B5	Prospectus Filed
Mar 28, 2024	10-K	Annual Report
Mar 27, 2024	SC 13G	Major Ownership Report
Mar 27, 2024	8-K	Current Report
Mar 22, 2024	8-K	Current Report
Mar 04, 2024	8-K	Current Report
Feb 16, 2024	SC 13G	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Durect Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	353.7B	85.2B	-5.73%	-9.70%	10.06	4.15	6.46%	95.94%
MRK	330.8B	60.1B	4.06%	15.15%	906.27	5.5	1.40%	-97.49%
AMGN	144.4B	28.2B	-4.38%	12.82%	21.5	5.12	7.09%	2.52%
PFE	142.6B	46.5B	-8.45%	-34.61%	-102.73	3.06	42.59%	-114.62%
GILD	81.3B	27.1B	-9.83%	-22.03%	14.36	3	-0.60%	23.36%
TEVA	14.8B	15.8B	-6.29%	61.39%	-25.76	0.94	6.17%	76.47%
MID-CAP
PRGO	4.2B	4.7B	1.56%	-13.21%	-333.67	0.91	4.58%	90.97%
ALKS	4.1B	1.7B	-8.63%	-13.78%	11.48	2.45	49.61%	324.78%
BHC	3.1B	8.8B	-12.58%	22.10%	-5.32	0.36	7.79%	-163.11%
AMPH	2.0B	644.4M	-5.53%	6.97%	14.28	3.05	29.14%	50.51%
SMALL-CAP
TLRY	1.4B	743.2M	-24.24%	-19.72%	-3.85	1.82	24.65%	80.36%
TXMD	21.6M	1.3M	-16.89%	-47.03%	-2.1	16.56	-98.14%	-109.18%
ACRX	18.8M	-	-0.89%	64.15%	-1.02	0.22	2882.68%	-138.52%
AGRX	2.7M	19.6M	21.21%	-93.94%	-0.19	0.14	80.00%	43.08%
ACOR	931.6K	117.6M	-96.48%	-95.45%	0	0.01	-0.79%	-283.60%

Durect Corp News

Latest updates

Durect Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q3	2019Q2
Revenue	53.0%	2,669	1,744	2,081	2,054	2,685	3,315	11,977	2,076	1,915	7,297	2,165	2,303	2,212	2,208	1,810	24,498	17,592	10,685	10,763	7,374	3,985
Costs and Expenses	-21.0%	8,923	11,301	12,132	13,076	-	14,813	14,109	13,162	12,281	13,809	11,623	10,960	11,858	10,517	10,638	10,157	11,414	10,948	12,474	-	10,755
S&GA Expenses	-30.0%	2,652	3,790	3,827	4,095	-	4,345	3,883	3,952	3,735	4,514	3,236	3,168	3,531	3,414	3,429	3,337	3,431	3,546	3,837	-	3,278
R&D Expenses	-22.0%	5,613	7,199	7,946	8,593	-	9,953	9,881	8,817	8,211	8,415	8,023	7,433	7,975	6,685	6,870	6,567	7,587	8,885	7,906	-	6,598
Interest Expenses	-	-	-	-	-	-	-	-	-	530	11.00	553	528	525	547	546	552	592	609	629	-	634
Net Income	52.2%	-1,441	-3,015	-11,181	-11,987	-	-10,469	-2,471	-11,551	-10,842	-7,008	-9,977	-9,146	-10,134	4,360	-9,332	14,338	-9,948	-4,231	-1,990	-	-7,227
Net Income Margin	5.7%	-3.23*	-3.43*	-2.81*	-2.43*	-2.06*	-1.83*	-1.37*	-2.93*	-2.70*	-2.59*	-2.80*	-2.84*	-0.02*	-	-	-	-	-	-	-	-
Free Cashflow	-11.1%	-8,325	-7,496	-9,361	-9,281	-8,429	-8,429	-2,258	-10,112	-5,592	-11,121	-7,523	-8,149	-10,712	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-17.4%	45.00	55.00	49.00	58.00	60.00	68.00	70.00	81.00	92.00	98.00	106	116	76.00	70.00	73.00	74.00	86.00	88.00	60.00	52.00	50.00
Current Assets	-20.8%	35.00	44.00	40.00	51.00	51.00	59.00	60.00	71.00	82.00	87.00	95.00	105	63.00	57.00	60.00	61.00	72.00	74.00	45.00	36.00	42.00
Cash Equivalents	-27.2%	28.00	39.00	32.00	39.00	43.00	51.00	47.00	50.00	50.00	56.00	56.00	58.00	21.00	19.00	19.00	33.00	35.00	40.00	37.00	28.00	32.00
Inventory	-12.0%	2.00	3.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	4.00	3.00	3.00	2.00	4.00	4.00	3.00	3.00
Net PPE	-28.3%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	0.00	0.00	1.00	1.00	1.00
Goodwill	0%	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Current Liabilities	-26.5%	27.00	37.00	41.00	42.00	34.00	13.00	11.00	9.00	10.00	10.00	8.00	12.00	11.00	10.00	10.00	24.00	37.00	41.00	11.00	10.00	8.00
Long Term Debt	-	-	-	-	-	-	18.00	20.00	21.00	21.00	20.00	20.00	18.00	20.00	21.00	21.00	20.00	20.00	18.00	20.00	21.00	21.00
LT Debt, Current	-10.9%	17.00	19.00	21.00	21.00	21.00	3.00	1.00	-	-	-	-	3.00	1.00	-	-	-	-	3.00	1.00	-	-
LT Debt, Non Current	-	-	-	-	-	-	18.00	20.00	21.00	21.00	20.00	20.00	18.00	20.00	21.00	21.00	20.00	20.00	18.00	20.00	21.00	21.00
Shareholder's Equity	2.6%	15.00	14.00	6.00	15.00	25.00	35.00	37.00	48.00	58.00	64.00	73.00	82.00	40.00	35.00	36.00	14.00	23.00	22.00	23.00	14.00	20.00
Retained Earnings	-0.2%	-589	-587	-584	-573	-561	-550	-548	-536	-526	-519	-509	-499	-489	-494	-484	-499	-489	-484	-482	-475	-468
Additional Paid-In Capital	0.3%	604	602	590	589	586	586	585	585	584	583	583	582	530	529	521	513	512	507	506	490	489
Accumulated Depreciation	-	15.00	-	-	-	19.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	20.5%	30.00	25.00	24.00	24.00	23.00	23.00	23.00	23.00	23.00	23.00	22.00	22.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	120	-	-	-	108	-	-	-	323	-	-	-	170	-	-	-	106	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-11.3%	-8,325	-7,483	-9,343	-9,263	-8,411	-2,229	-10,081	-5,559	-11,111	-7,359	-8,132	-10,709	-8,380	-8,684	-8,780	-12,860	3,977	18,789	-6,009	-5,656	-6,099
Share Based Compensation	-6.9%	616	661	659	602	583	578	618	678	623	653	710	702	659	604	464	414	399	850	422	437	1,159
Cashflow From Investing	-135.0%	-1,034	2,951	1,841	-4,924	1,476	5,463	7,750	5,147	5,392	6,815	7,210	-4,106	10,572	1,805	-12,698	9,753	-12,639	-16,248	-33.00	1,596	385
Cashflow From Financing	-110.4%	-1,226	11,757	-34.00	10,000	24.00	25.00	26.00	8.00	151	-117	-550	51,048	450	7,103	7,347	760	3,860	242	15,344	57.00	-859

DRRX Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Total revenues	$ 8,548	$ 19,283	$ 13,977
Operating expenses:
Cost of product revenues	$ 1,717	$ 1,588	$ 1,955
Type of cost, good or service [extensible list]	Product Revenue, Net [Member]	Product Revenue, Net [Member]	Product Revenue, Net [Member]
Research and development	$ 29,351	$ 36,862	$ 31,846
Selling, general and administrative	14,364	15,915	14,449
Total operating expenses	45,432	54,365	48,250
Loss from operations	(36,884)	(35,082)	(34,273)
Other income (expense):
Interest and other income	2,129	2,148	156
Interest and other expenses	(2,792)	(2,399)	(2,148)
Change in fair value of warrant liabilities	13,583
Issuance cost for warrants	(1,627)
Loss on issuance of warrants	(2,033)
Other income (expense), net	9,260	(251)	(1,992)
Net loss	(27,624)	(35,333)	(36,265)
Net change in unrealized loss on available-for-sale securities, net of reclassification adjustments and taxes	(1)	(3)	(5)
Total comprehensive loss	$ (27,625)	$ (35,336)	$ (36,270)
Net loss per share
Net income per share, basic	$ (1.05)	$ (1.55)	$ (1.61)
Net income per share, diluted	$ (1.2)	$ (1.55)	$ (1.61)
Weighted-average shares used in computing net loss per share
Weighted-average shares used in computing net loss per share, basic	26,256	22,777	22,505
Weighted-average shares used in computing net loss per share, diluted	26,520	22,777	22,505
Collaborative Research and Development and Other Revenue [Member]
Total revenues	$ 2,277	$ 13,204	$ 6,331
Product Revenue, Net [Member]
Total revenues	$ 6,271	$ 6,079	$ 7,646

DRRX Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 28,400	$ 43,483
Short-term investments	1,280
Accounts receivable (net of allowances of $20 at December 31, 2023 and $21 at December 31, 2022)	1,261	3,423
Inventories, net	2,219	2,113
Prepaid expenses and other current assets	1,511	2,375
Total current assets	34,671	51,394
Property and equipment, net	91	188
Operating lease right-of-use assets	3,980	1,943
Goodwill	6,169	6,169
Long-term restricted investments	150	150
Other long-term assets	128	256
Total assets	45,189	60,100
Current liabilities:
Accounts payable	1,777	3,106
Accrued liabilities	5,966	7,896
Term loan, current portion, net	16,663	21,170
Operating lease liabilities, current portion	1,381	1,832
Warrant liabilities	1,224
Total current liabilities	27,011	34,004
Operating lease liabilities, non-current portion	2,702	260
Other long-term liabilities	693	851
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value: 10,000 shares authorized; none issued and outstanding
Common stock, $0.0001 par value: 150,000 shares authorized at December 31, 2023 and 2022, respectively; 30,334 and 22,785 shares issued and outstanding at December 31, 2023 and 2022, respectively	23	23
Additional paid-in capital	603,780	586,357
Accumulated other comprehensive loss	(14)	(13)
Accumulated deficit	(589,006)	(561,382)
Stockholders’ equity	14,783	24,985
Total liabilities and stockholders’ equity	$ 45,189	$ 60,100

About Durect Corp

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

CEO	Dr. James E. Brown D.V.M.
WEBSITE	durect.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	72

Durect Corp Frequently Asked Questions

What is the ticker symbol for Durect Corp? What does DRRX stand for in stocks?

DRRX is the stock ticker symbol of Durect Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Durect Corp (DRRX)?

As of Thu Apr 25 2024, market cap of Durect Corp is 28.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DRRX stock?

You can check DRRX's fair value in chart for subscribers.

What is the fair value of DRRX stock?

You can check DRRX's fair value in chart for subscribers. The fair value of Durect Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Durect Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DRRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Durect Corp a good stock to buy?

The fair value guage provides a quick view whether DRRX is over valued or under valued. Whether Durect Corp is cheap or expensive depends on the assumptions which impact Durect Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DRRX.

What is Durect Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Apr 25 2024, DRRX's PE ratio (Price to Earnings) is -1.03 and Price to Sales (PS) ratio is 3.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DRRX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Durect Corp's stock?

In the past 10 years, Durect Corp has provided -0.035 (multiply by 100 for percentage) rate of return.